Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection
A blood test combined with imaging before surgery could help doctors identify which colorectal cancer patients need closer monitoring after treatment.
This study from the GALAXY trial prospectively tested an integrated model combining preoperative ctDNA levels with radiographic tumor volume to predict recurrence after surgical resection of colorectal cancer liver and lung metastases in 229 patients. The combined ctDNA/volume model robustly separated high- and low-risk groups for postoperative progression-free survival, demonstrating clinical utility beyond either marker alone.
What the study was
- Study design
- Prospective cohort (registry-based, GALAXY trial participants)
- Population
- Colorectal cancer patients with curatively resectable liver or lung metastases
- Sample size
- 229
- Category
- Early Detection
- Maturity
- Validated
- Journal
- NPJ Precision Oncology
Why it surfaced
Prospective GALAXY trial sub-study (N=229) demonstrating a ctDNA+imaging integrated model that significantly stratifies post-resection recurrence risk in CRC metastatic patients. Clinically actionable, directly informs perioperative management and surveillance strategy. High journal impact (NPJ Precision Oncology).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.